Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine

Stock Track11-27 15:46

Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.

China's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal diseases caused by serogroups A, C, Y, and W-135.

The positive regulatory development for Menhycia, a key pipeline asset for CanSinoBIO, has been welcomed by investors as it potentially expands the addressable market for the vaccine in China. The stock's surge reflects the market's optimism about the company's prospects and growth potential in the domestic vaccine market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177192004?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177192004","market":"us","top_or_hot":-1,"title":"Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine","media":"Stock Track","content":"<p>Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.</p>\n\n<p>China's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal diseases caused by serogroups A, C, Y, and W-135.</p>\n\n<p>The positive regulatory development for Menhycia, a key pipeline asset for CanSinoBIO, has been welcomed by investors as it potentially expands the addressable market for the vaccine in China. The stock's surge reflects the market's optimism about the company's prospects and growth potential in the domestic vaccine market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-27 15:46 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.\nChina's ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1177192004","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177192004","pubTimestamp":1732693593,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.China's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"脑膜炎球菌疫苗监管更新积极，康希诺生物股价飙升5.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.\nChina's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal diseases caused by serogroups A, C, Y, and W-135.\nThe positive regulatory development for Menhycia, a key pipeline asset for CanSinoBIO, has been welcomed by investors as it potentially expands the addressable market for the vaccine in China. The stock's surge reflects the market's optimism about the company's prospects and growth potential in the domestic vaccine market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177192004"}